Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 16/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.38 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2835140 | 0.86 | KIF11 (0.53) | KIF11 | |
| SCHEMBL2840135 | 0.80 | KIF11 (0.43) | KIF11KCNH2 | |
| SCHEMBL2840134 | 0.78 | KIF11 (0.46) | KIF11 | |
| SCHEMBL6026088 | 0.74 | FFAR4 (0.45) | KIF11 | |
| SCHEMBL3427137 | 0.74 | FFAR4 (0.45) | KIF11 | |
| SCHEMBL34261 | 0.73 | KIF11 (0.56) | KIF11 | |
| SCHEMBL17189279 | 0.72 | KIF11 (0.53) | KIF11KCNH2 | |
| SCHEMBL4397129 | 0.72 | KIF11 (0.78) | KIF11 | |
| SCHEMBL27608746 | 0.72 | KIF11 (0.78) | KIF11 | |
| SCHEMBL8035494 | 0.72 | CYP4F2 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100228012-A1 | PENDANT FATTY ACID IMAGING AGENTS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-7556794-B2 | Pendant fatty acid imaging agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20070128119-A1 | Pendant fatty acid imaging agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| US-7179444-B2 | Pendant fatty acid imaging agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| EP-1490114-A1 | PENDANT FATTY ACID IMAGING AGENTS | Biostream, Inc. (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040081616-A1 | Pendant fatty acid imaging agents | BIOSTREAM, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2003084575-A1 | PENDANT FATTY ACID IMAGING AGENTS | BIOSTREAM, INC. (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070128119-A1 | Pendant fatty acid imaging agents | FABP3, CPT1B, FABP1 | KIF11 1443/4885KCNH2 4040/4885GRIN2D 4789/4885 |
| US-20100228012-A1 | PENDANT FATTY ACID IMAGING AGENTS | FABP3, CPT1B, FABP1 | KIF11 1443/4885KCNH2 4040/4885GRIN2D 4789/4885 |
| US-20040081616-A1 | Pendant fatty acid imaging agents | FABP3, CPT1B, FABP1 | KIF11 1443/4885KCNH2 4040/4885GRIN2D 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.